Fosnetupitant

Drug profile

Key facts

Fosnetupitant is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2018. DrugCentral lists 1 molecular target, including TACR1. Recorded indications include Chemotherapy-induced nausea and vomiting.

• Approval status: onp (first approved 2018 by the FDA).
• Molecular targets: TACR1 (1 listed in DrugCentral).
• Indications: Chemotherapy-induced nausea and vomiting.
• Molecular formula: C31H36F6N4O5P; molecular weight 689.62 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Chemotherapy-induced nausea and vomiting

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Substance-P receptor	TACR1	antagonist	Ki 9.02

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2022-03-28	PMDA	—	Taiho Pharmaceutical Co., Ltd.
2018-04-19	FDA	—	HELSINN HLTHCARE

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Triple negative breast cancer	253.1
Febrile neutropenia	68.3
Neutropenia	67.9
Decreased appetite	64.2
Neutrophil count decreased	62.8
Hypoalbuminaemia	54.0
Nausea	48.9
Flushing	43.2
Hypokalaemia	36.4

Chemical structure

• Molecular formula: C₃₁H₃₆F₆N₄O₅P
• Molecular weight: 689.62 g/mol
• CAS number: 1703748-89-3
• InChIKey: HZIYEEMJNBKMJH-UHFFFAOYSA-O
• PubChem CID: 71544786

CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=C(C)C=CC=C1)N1CC[N+](C)(COP(O)(O)=O)CC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Fosnetupitant used for?

DrugCentral lists the following indications for Fosnetupitant: Chemotherapy-induced nausea and vomiting.

How does Fosnetupitant work?

Its molecular targets in DrugCentral include TACR1 (antagonist).

When was Fosnetupitant first approved?

Fosnetupitant was first approved by the FDA in 2018.

What is the chemical formula of Fosnetupitant?

Fosnetupitant has the molecular formula C31H36F6N4O5P and a molecular weight of 689.62 g/mol.

Sources

• DrugCentral drug card 5283 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3989917 — compound record and bioactivity
• PubChem CID 71544786 — chemical identifiers
• DrugBank DB14019 — drug record
• FDA UNII T672P80L2S — substance identity
• DailyMed: FDA labels for Fosnetupitant — current prescribing information (label search)
• UniProt P25103 (TACR1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.